Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) EBIT: 2010-2024

Historic EBIT for Ani Pharmaceuticals (ANIP) over the last 15 years, with Dec 2024 value amounting to $584,000.

  • Ani Pharmaceuticals' EBIT rose 276.62% to $36.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.9 million, marking a year-over-year increase of 515.57%. This contributed to the annual value of $584,000 for FY2024, which is 98.76% down from last year.
  • Ani Pharmaceuticals' EBIT amounted to $584,000 in FY2024, which was down 98.76% from $47.0 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' EBIT registered a high of $47.0 million during FY2023, and its lowest value of -$39.8 million during FY2021.
  • In the last 3 years, Ani Pharmaceuticals' EBIT had a median value of $584,000 in 2024 and averaged $4.1 million.
  • Its EBIT has fluctuated over the past 5 years, first crashed by 197.95% in 2020, then spiked by 233.13% in 2023.
  • Ani Pharmaceuticals' EBIT (Yearly) stood at -$16.0 million in 2020, then slumped by 148.46% to -$39.8 million in 2021, then increased by 11.33% to -$35.3 million in 2022, then skyrocketed by 233.13% to $47.0 million in 2023, then slumped by 98.76% to $584,000 in 2024.